SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial Results

Rhea-AI Summary

SANUWAVE Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced it will host a conference call on November 8, 2024, at 8:30 AM (ET) to discuss its Q3 2024 financial results. Participants can join via toll-free number 1-800-267-6316 or international number 1-203-518-9783 using Conference ID: SANUWAVE. Materials will be available on the company's website, and a replay will be accessible through November 29, 2024, using replay access ID: 11157276.

EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 8, 2024, at 8:30 AM (ET) to present its Q3 2024 financial results.

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information

Toll Free: 1-800-267-6316

Toll/International: 1-203-518-9783

Conference ID: SANUWAVE

OR click the link for instant telephone access to the event:
https://viavid.webcasts.com/starthere.jsp?ei=1692398&tp_key=e3cff43c54

Materials for the conference call will be included on the Company’s website at www.sanuwave.com/investors.

A replay will be made available through November 29, 2024:

Toll-Free: 1-844-512-2921 or 1-412-317-6671

Replay Access ID: 11157276

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with supply chain and production constraints, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact:
investors@sanuwave.com

FAQ

When will SANUWAVE Health (SNWV) report Q3 2024 earnings?

SANUWAVE Health will report Q3 2024 earnings on November 8, 2024, at 8:30 AM ET via conference call.

How can investors access SANUWAVE's (SNWV) Q3 2024 earnings call?

Investors can access the call by dialing 1-800-267-6316 (toll-free) or 1-203-518-9783 (international) with Conference ID: SANUWAVE, or through the webcast link provided.

Until when will SANUWAVE's (SNWV) Q3 2024 earnings call replay be available?

The earnings call replay will be available through November 29, 2024, using replay access ID: 11157276.